Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicentre Real-World Study.
2 June 2025. doid: 10.1111/cea.70067
Soegiharto R, Van der Wind E, Alizadeh Aghdam M, Sørensen JA, Van Lindonk E, Bulut Demir F, Mohammad Porras N, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Fachini Jardim Criado R, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Oztas Kara R, Sevimli Dikicier B, Van Doorn MBA, Thomsen SF, Van den Reek JMPA, Röckmann H
View publicationChronic urticaria (CU) treatment with omalizumab is considered safe in short-term studies. Large real-world studies focusing on the long-term safety of omalizumab and associated factors are lacking. We aimed to investigate the spectrum of reported side effects in omalizumab-treated CU patients in a large long-term daily practice cohort.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
